Effects of a nutraceutical multicomponent supplement (Vertilev®) in older people with chronic dizziness: a prospective, open-label, single-arm multicenter study

Chronic dizziness and postural instability are highly prevalent in the elderly population, affecting 10-30% of individuals over 65, substantially impairing quality of life and increasing fall risk. This condition, often called "presbystasis", arises from progressive deterioration of vestibular, visual, and proprioceptive inputs and is frequently associated with central microcirculatory disturbances....

Continue reading at PubMed →

No actionable change — the open-label, single-arm design without a placebo control means any apparent benefit from Vertilev® cannot be distinguished from natural history or expectation effects; audiologists and vestibular specialists should not recommend this supplement based on this study alone.

Chronic dizziness in the elderly is prevalent and undertreated, so interest in nutraceutical adjuncts is high, but rigorous placebo-controlled evidence is needed before these products can be endorsed in clinical vestibular rehabilitation guidelines.

1. 01Vertilev® is a multicomponent nutraceutical (supplement blend) evaluated for chronic dizziness in adults 65+.
2. 02Prospective, open-label, single-arm design — no placebo or active comparator group.
3. 03Chronic dizziness affects an estimated 10–30% of adults over 65, representing a large potential market.
4. 04Open-label design introduces substantial placebo and expectation bias, limiting conclusions.
5. 05Published in Panminerva Medica (2026); doi: 10.23736/S0031-0808.26.05450-9.

PMID

42986319

DOI

10.23736/S0031-0808.26.05450-9.

Journal

Panminerva Medica

Publication type

research_article

Evidence level

2b

Population

Adults over 65 with chronic dizziness and postural instability

Intervention

Vertilev® nutraceutical multicomponent supplement